Humanwell Healthcare Group Co Ltd (600079) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Humanwell Healthcare Group Co Ltd (600079) has a cash flow conversion efficiency ratio of 0.048x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥903.00 Million ≈ $132.14 Million USD) by net assets (CN¥18.96 Billion ≈ $2.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 600079 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Humanwell Healthcare Group Co Ltd - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Humanwell Healthcare Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Humanwell Healthcare Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humanwell Healthcare Group Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Veradermics, Incorporated
NYSE:MANE
|
-0.054x |
|
United Community Banks, Inc.
NYSE:UCB
|
0.019x |
|
Gland Pharma Limited
NSE:GLAND
|
0.057x |
|
MAZDA MOTOR UNSP.ADR/2
F:MZA0
|
N/A |
|
Nordic Semiconductor ASA
OL:NOD
|
0.001x |
|
Titan Cement International SA
BR:TITC
|
0.084x |
|
Shanghai Moons' Elec Co Ltd
SHG:603728
|
0.020x |
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
0.002x |
Annual Cash Flow Conversion Efficiency for Humanwell Healthcare Group Co Ltd (2000–2024)
The table below shows the annual cash flow conversion efficiency of Humanwell Healthcare Group Co Ltd from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see Humanwell Healthcare Group Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥20.69 Billion ≈ $3.03 Billion |
CN¥2.16 Billion ≈ $316.70 Million |
0.105x | +6.85% |
| 2023-12-31 | CN¥20.10 Billion ≈ $2.94 Billion |
CN¥1.97 Billion ≈ $287.87 Million |
0.098x | -28.06% |
| 2022-12-31 | CN¥17.94 Billion ≈ $2.63 Billion |
CN¥2.44 Billion ≈ $357.21 Million |
0.136x | -2.28% |
| 2021-12-31 | CN¥15.65 Billion ≈ $2.29 Billion |
CN¥2.18 Billion ≈ $318.83 Million |
0.139x | -13.81% |
| 2020-12-31 | CN¥12.94 Billion ≈ $1.89 Billion |
CN¥2.09 Billion ≈ $305.80 Million |
0.162x | +10.95% |
| 2019-12-31 | CN¥14.00 Billion ≈ $2.05 Billion |
CN¥2.04 Billion ≈ $298.20 Million |
0.146x | +244.59% |
| 2018-12-31 | CN¥14.27 Billion ≈ $2.09 Billion |
CN¥602.99 Million ≈ $88.24 Million |
0.042x | +651.64% |
| 2017-12-31 | CN¥16.61 Billion ≈ $2.43 Billion |
CN¥93.35 Million ≈ $13.66 Million |
0.006x | -87.21% |
| 2016-12-31 | CN¥11.98 Billion ≈ $1.75 Billion |
CN¥526.48 Million ≈ $77.04 Million |
0.044x | +29.63% |
| 2015-12-31 | CN¥9.18 Billion ≈ $1.34 Billion |
CN¥311.22 Million ≈ $45.54 Million |
0.034x | -61.38% |
| 2014-12-31 | CN¥5.73 Billion ≈ $838.16 Million |
CN¥502.70 Million ≈ $73.56 Million |
0.088x | -10.50% |
| 2013-12-31 | CN¥5.08 Billion ≈ $743.41 Million |
CN¥498.22 Million ≈ $72.90 Million |
0.098x | +107.76% |
| 2012-12-31 | CN¥3.65 Billion ≈ $534.05 Million |
CN¥172.27 Million ≈ $25.21 Million |
0.047x | +57.24% |
| 2011-12-31 | CN¥3.14 Billion ≈ $459.33 Million |
CN¥94.23 Million ≈ $13.79 Million |
0.030x | -37.27% |
| 2010-12-31 | CN¥2.33 Billion ≈ $340.61 Million |
CN¥111.39 Million ≈ $16.30 Million |
0.048x | -35.55% |
| 2009-12-31 | CN¥2.08 Billion ≈ $304.49 Million |
CN¥154.51 Million ≈ $22.61 Million |
0.074x | +163.33% |
| 2008-12-31 | CN¥1.24 Billion ≈ $181.47 Million |
CN¥34.97 Million ≈ $5.12 Million |
0.028x | -40.22% |
| 2007-12-31 | CN¥1.17 Billion ≈ $170.79 Million |
CN¥55.05 Million ≈ $8.06 Million |
0.047x | -38.05% |
| 2006-12-31 | CN¥1.11 Billion ≈ $162.28 Million |
CN¥84.44 Million ≈ $12.36 Million |
0.076x | -53.95% |
| 2005-12-31 | CN¥768.89 Million ≈ $112.51 Million |
CN¥127.13 Million ≈ $18.60 Million |
0.165x | +69.80% |
| 2004-12-31 | CN¥724.52 Million ≈ $106.02 Million |
CN¥70.55 Million ≈ $10.32 Million |
0.097x | +37.38% |
| 2003-12-31 | CN¥681.54 Million ≈ $99.73 Million |
CN¥48.31 Million ≈ $7.07 Million |
0.071x | +66.56% |
| 2001-12-31 | CN¥396.54 Million ≈ $58.03 Million |
CN¥16.88 Million ≈ $2.47 Million |
0.043x | -47.20% |
| 2000-12-31 | CN¥325.09 Million ≈ $47.57 Million |
CN¥26.20 Million ≈ $3.83 Million |
0.081x | -- |
About Humanwell Healthcare Group Co Ltd
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for pa… Read more